1. Home
  2. CAPR vs ORN Comparison

CAPR vs ORN Comparison

Compare CAPR & ORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • ORN
  • Stock Information
  • Founded
  • CAPR 2005
  • ORN 1994
  • Country
  • CAPR United States
  • ORN United States
  • Employees
  • CAPR N/A
  • ORN N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • ORN Military/Government/Technical
  • Sector
  • CAPR Health Care
  • ORN Industrials
  • Exchange
  • CAPR Nasdaq
  • ORN Nasdaq
  • Market Cap
  • CAPR 324.6M
  • ORN 339.4M
  • IPO Year
  • CAPR N/A
  • ORN 2007
  • Fundamental
  • Price
  • CAPR $6.08
  • ORN $7.87
  • Analyst Decision
  • CAPR Strong Buy
  • ORN Strong Buy
  • Analyst Count
  • CAPR 8
  • ORN 2
  • Target Price
  • CAPR $24.75
  • ORN $11.25
  • AVG Volume (30 Days)
  • CAPR 1.2M
  • ORN 445.4K
  • Earning Date
  • CAPR 11-12-2025
  • ORN 10-29-2025
  • Dividend Yield
  • CAPR N/A
  • ORN N/A
  • EPS Growth
  • CAPR N/A
  • ORN N/A
  • EPS
  • CAPR N/A
  • ORN 0.27
  • Revenue
  • CAPR $13,392,150.00
  • ORN $837,494,000.00
  • Revenue This Year
  • CAPR N/A
  • ORN $4.83
  • Revenue Next Year
  • CAPR $7,894.07
  • ORN $8.34
  • P/E Ratio
  • CAPR N/A
  • ORN $28.95
  • Revenue Growth
  • CAPR N/A
  • ORN 15.85
  • 52 Week Low
  • CAPR $4.59
  • ORN $4.64
  • 52 Week High
  • CAPR $23.40
  • ORN $9.95
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 40.13
  • ORN 57.53
  • Support Level
  • CAPR $5.97
  • ORN $7.48
  • Resistance Level
  • CAPR $6.57
  • ORN $7.71
  • Average True Range (ATR)
  • CAPR 0.38
  • ORN 0.34
  • MACD
  • CAPR 0.03
  • ORN 0.10
  • Stochastic Oscillator
  • CAPR 36.70
  • ORN 60.31

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About ORN Orion Group Holdings Inc. Common

Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar and mesh across the light commercial, structural and other associated business areas.

Share on Social Networks: